Priority Health to cover FoundationOne genomic profiles

ACS strengthens recommendation for prostate cancer screening
Many will hear the endorsement and ignore the limitations

For nearly 30 years, the American Cancer Society’s prostate cancer screening guidelines have advised men to discuss prostate-specific antigen, or PSA, testing with a clinician and weigh potential benefits and harms, rather than treat screening as an unquestioned routine. This “informed decision-making” recommendation was consistent with guidelines from all major professional organizations in the United States, Canada, and Europe.

November 13, 2026

Vol.52 No.42

By Otis W. Brawley and Ian Schonman

Regulatory News

NCI’s Letai, FDA’s Diamantas identify strategies to speed up cancer trials
Letai: 150 days to start a cancer trial is too long—cancer centers need to accept a little risk

NCI Director Anthony Letai wants cancer centers and pharmaceutical companies to move faster on clinical trial contracts.

November 13, 2026

Vol.52 No.42

By Claire Marie Porter

CMS rule cuts overall oncology payments by estimated 2%
Final rule slashes 340B, moves toward site-neutrality

The Centers for Medicare and Medicaid Services last week published the long-awaited—or long-dreaded—final rule governing Medicare reimbursement of the Hospital Outpatient Prospective Payment System.

Kay “Taddy” Dickersin, NBCC co-founder, dies at 74

Dr. Kay “Taddy” Dickersin, PhD, MA, who had a hand in every aspect of the National Breast Cancer Coalition’s work, died Nov. 1 from complications of progressive supranuclear palsy. She was 74.

November 13, 2026

Vol.52 No.42

By Frances M. Visco

Cancer History Project

In the 90s, Barry Kramer persuaded NCI to get out of the business of screening guidelines
At the time, USPSTF was better equipped to do the job. Is it still?

When Barnett Kramer joined the National Cancer Institute as a young physician in 1986,his work centered on caring for patients and conducting therapeutic research.

November 13, 2026

Vol.52 No.42

By Sara Willa Ernst

Clinical trial aims to personalize treatment for patients with HPV-related throat cancer
Blood-based protocol could reduce treatment burden while preserving quality of life after surgery

For patients with an HPV-related form of throat cancer, treatment is often highly effective, with cure rates as high as 90%, depending on the disease stage. Now, researchers are investigating whether some patients can safely avoid additional treatment while maintaining excellent cancer outcomes.

November 13, 2026

Vol.52 No.42

By Hayley Kamin

Priority Health to cover FoundationOne genomic profiles

YOU MAY BE INTERESTED IN

ACS strengthens recommendation for prostate cancer screening
Many will hear the endorsement and ignore the limitations

NCI’s Letai, FDA’s Diamantas identify strategies to speed up cancer trials
Letai: 150 days to start a cancer trial is too long—cancer centers need to accept a little risk

CMS rule cuts overall oncology payments by estimated 2%
Final rule slashes 340B, moves toward site-neutrality

Kay “Taddy” Dickersin, NBCC co-founder, dies at 74

In the 90s, Barry Kramer persuaded NCI to get out of the business of screening guidelines
At the time, USPSTF was better equipped to do the job. Is it still?

Clinical trial aims to personalize treatment for patients with HPV-related throat cancer
Blood-based protocol could reduce treatment burden while preserving quality of life after surgery

Renew today!

Subscriber content

Never miss an issue!

Login

Priority Health to cover FoundationOne genomic profiles

YOU MAY BE INTERESTED IN

ACS strengthens recommendation for prostate cancer screeningMany will hear the endorsement and ignore the limitations

NCI’s Letai, FDA’s Diamantas identify strategies to speed up cancer trialsLetai: 150 days to start a cancer trial is too long—cancer centers need to accept a little risk

CMS rule cuts overall oncology payments by estimated 2%Final rule slashes 340B, moves toward site-neutrality

Kay “Taddy” Dickersin, NBCC co-founder, dies at 74

In the 90s, Barry Kramer persuaded NCI to get out of the business of screening guidelinesAt the time, USPSTF was better equipped to do the job. Is it still?

Clinical trial aims to personalize treatment for patients with HPV-related throat cancerBlood-based protocol could reduce treatment burden while preserving quality of life after surgery

Never miss an issue!

Login

ACS strengthens recommendation for prostate cancer screening
Many will hear the endorsement and ignore the limitations

NCI’s Letai, FDA’s Diamantas identify strategies to speed up cancer trials
Letai: 150 days to start a cancer trial is too long—cancer centers need to accept a little risk

CMS rule cuts overall oncology payments by estimated 2%
Final rule slashes 340B, moves toward site-neutrality

In the 90s, Barry Kramer persuaded NCI to get out of the business of screening guidelines
At the time, USPSTF was better equipped to do the job. Is it still?

Clinical trial aims to personalize treatment for patients with HPV-related throat cancer
Blood-based protocol could reduce treatment burden while preserving quality of life after surgery